A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Digoxin is the primary cardiac glycoside in clinical use. Because of the narrow therapeutic index and risk of toxicity, therapeutic drug monitoring is highly recommended. In Egypt, most cardiologists give digoxin holiday for both atrial fibrillation and heart failure, it is not clear if the interrupted digoxin regimens are effective since serum digoxin concentrations might fall below the therapeutic range.

Objective: To evaluate and compare the digoxin serum concentration and patient's quality of life in the continuous versus interrupted digoxin dosing regimens.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Digoxin

Criteria

Inclusion Criteria:

• Patients with atrial fibrillation (AF)

• with or without congestive heart failure (CHF)

• taking digoxin tablets with or without holiday regimens

Exclusion Criteria:

• taking the following drugs concurrently: amiodarone, verapamil, quinidine and propafenone.

• diagnosed with thyroid disorders (hyperthyroidism & hypothyroidism).

• diagnosed with renal failure

• pregnant